THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. 

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.

About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines.

For additional information, please visit www.lexpharma.com.   

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

Multi-tenant platform combines fixed-wing VTOL drone operations, crop intelligence, targeted treatment planning, and mission management

Product information and an interactive demonstration are available at evafarmsight.com

LAS VEGAS, NV, Oct. 29, 2026 (GLOBE NEWSWIRE) — Eva Live Inc. (NASDAQ: GOAI) (“Eva” or the “Company”), an artificial intelligence and autonomous technology company, today announced EvaFarmSight, an AI-powered precision agriculture platform designed to connect machine vision, fixed-wing vertical takeoff and landing drone operations, crop monitoring, and field-level decision support.

The public website and interactive product demonstration are available at evafarmsight.com. Current customers can use the same site to sign in to their organization’s secure operating environment.

The initiative marks Eva’s expansion into a major new commercial market, leveraging the Company’s existing investments in artificial intelligence and autonomous systems to address the growing demand for agricultural automation.

According to Grand View Research, the global precision farming market is projected to expand from approximately $16.8 billion in 2026 to $38.8 billion by 2033, representing a compound annual growth rate of 12.7%.

The agricultural drone market, a segment within the broader agricultural technology ecosystem, is separately projected to reach $13.2 billion by 2033, growing at 18.8% annually.

Eva believes these trends present a significant opportunity for companies capable of combining autonomous aerial systems with sophisticated AI analytics.

From Autonomous Defense Technology to the World’s Farmlands

Through its Eva Defense initiative, Eva has been developing autonomous drone concepts, machine vision capabilities, and AI-driven technologies intended for demanding operational environments.

Now, Eva intends to apply relevant elements of those technologies to a different mission: helping farmers protect crops, reduce waste, and operate more efficiently.

EvaFarmSight is designed as a secure, multi-tenant agricultural operations platform that transforms aerial imagery and field data into findings, targeted treatment plans, and flight missions that farm teams can review and manage.

“The same artificial intelligence that can help an autonomous drone identify an object in a complex environment can also help a farmer identify a crop problem across thousands of acres,” said David Boulette, Chief Executive Officer of Eva Live Inc.

“We believe the future of farming will involve autonomous drones continuously gathering intelligence while AI analyzes field conditions and helps farmers make better decisions. Our goal is to make that future practical, affordable, and scalable.”

Giving Every Acre an AI-Powered Eye in the Sky

EvaFarmSight is being designed around a simple concept: farmers should not have to physically inspect every acre to understand what is happening across their land.

The platform’s current and planned capabilities include:

  • AI Crop Health Detection: Analyze aerial imagery for signs of potential disease, pest activity, crop stress, and abnormal vegetation patterns, with findings organized by severity and confidence.
  • Fixed-Wing VTOL Survey Operations: Support repeatable aerial inspections using long-range aircraft that combine vertical takeoff and landing with efficient fixed-wing field coverage.
  • Targeted Treatment Planning: Convert reviewed crop findings into treatment zones and draft prescriptions so farm teams can focus applications on affected areas.
  • Precision Water Management: Detect potential irrigation problems, uneven moisture, and drainage patterns that may require field inspection.
  • Field Intelligence and Records: Maintain field-level crop information, survey history, findings, and aerial records throughout the growing season.
  • Mission and Fleet Management: Plan survey, treatment, and verification missions while monitoring aircraft readiness, battery status, and flight activity.
  • Multi-Tenant Agricultural Operations: Separate each customer organization’s farms, fields, aircraft, missions, and user access within a shared platform architecture.

The Company’s longer-term vision includes integrating autonomous aerial monitoring with AI software to create a continuously improving agricultural intelligence system.

A New Recurring Revenue Opportunity for Eva

EvaFarmSight is intended to create opportunities for recurring software revenue, enterprise agricultural licensing, and autonomous monitoring services.

Potential commercial models include subscription-based crop analytics, per-acre monitoring services, enterprise platform licensing, and partnerships with agricultural equipment providers and drone operators.

Unlike traditional agricultural equipment businesses that rely primarily on hardware sales, Eva intends to explore a software-centric model that could generate recurring revenue as farmers use the platform throughout successive growing seasons.

The Company believes this approach could allow EvaFarmSight to scale through agricultural service providers and technology partners without requiring Eva to manufacture or operate every drone used by customers.

Artificial Intelligence Is Moving Beyond the Data Center

EvaFarmSight reflects a broader strategic direction for Eva: commercializing artificial intelligence in industries where software can directly influence real-world operations.

The Company’s initiatives span enterprise AI, autonomous defense systems, machine vision, and now agricultural intelligence.

By applying related technology capabilities across multiple markets, Eva aims to create additional commercialization opportunities from its core research and development activities.

“Agriculture represents a tremendous opportunity because the value of better information can be measured in real economic terms,” Boulette added.

“A farmer who identifies a developing problem earlier may be able to protect an entire section of a field. A farm that optimizes water and fertilizer usage can potentially improve its economics. We want EvaFarmSight to put advanced AI technology to work where those improvements matter.”

Product Platform and Commercial Development

The EvaFarmSight web platform provides a public product overview and interactive demonstration. Within the operating environment, farm teams can review crop health, examine findings by severity and confidence, prepare targeted treatment prescriptions, plan missions, and monitor VTOL aircraft readiness.

The platform uses organization-based roles and server-side tenant controls to separate each customer’s operational data. Eva intends to continue validating EvaFarmSight with agricultural operators, developing industry partnerships, and advancing its autonomous monitoring and analytics capabilities.

Learn more and explore the product at evafarmsight.com.

About Eva Live Inc.

Eva Live Inc. (NASDAQ: GOAI) is an artificial intelligence technology company focused on developing and commercializing advanced AI software, autonomous systems, and intelligent applications across multiple industries. Through its technology initiatives, including Eva Defense, the Company is pursuing opportunities in enterprise artificial intelligence, autonomous technology, machine vision, digital media, and emerging commercial applications.

For more information, visit www.eva.live.

Market Research Sources

Grand View Research, Precision Farming Market Size & Share Report, 2026–2033, June 2026.

Grand View Research, Agriculture Drones Market Size & Share Report, 2026–2033, June 2026.

The market estimates represent third-party industry projections and do not constitute Company revenue forecasts or estimates of EvaFarmSight’s obtainable market share.

Cautionary Note Regarding Forward-Looking Statements.

This press release contains “forward-looking statements” within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included herein, including but not limited to such things as future business strategy, plans, and goals, and the expansion and growth of our business. The words “estimate”, “plan”, “anticipate”, “expect”, “intend”, “believe” “target”, “budget”, “may”, “can”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to” and similar words or expressions, or negatives of these terms or other variations of these terms or comparable language or any discussion of strategy or intention identify forward-looking statements. Please see the risk factors included in the Company’s United States Securities and Exchange Commission filings, which could cause actual results and events to differ materially from those contained in the forward-looking statements. You are cautioned against attributing undue certainty to forward-looking statements. Although these forward-looking statements were based on assumptions that the Company believes are reasonable when made, you are cautioned that forward-looking statements are not guarantees of future performance and that actual results, performance, or achievements may differ materially from those made in or suggested by the forward-looking statements in this press release. Any forward-looking statements made in this press release speak only as of the date of those statements. We undertake no obligation to update those statements or publicly announce the results of any revisions to any of those statements to reflect future events or developments.

Media Inquiries:
Javan Khazali
Phone: 310-229-5981
Email: info@eva.live
Website: @eva.live
Instagram: @eva.liveinc
Facebook: @evaliveinc
X: @evaliveinc1
LinkedIn: @eva-live
Youtube: @evaliveinc

WEST DES MOINES, Iowa, Oct. 29, 2026 (GLOBE NEWSWIRE) — West Bancorporation, Inc. (Nasdaq: WTBA; the “Company”), parent company of West Bank, today reported third quarter 2026 net income of $11.6 million, or $0.67 per diluted common share, compared to second quarter 2026 net income of $11.1 million, or $0.64 per diluted common share, and third quarter 2025 net income of $9.3 million, or $0.55 per diluted common share. On October 28, 2026, the Company’s Board of Directors declared a regular quarterly dividend of $0.26 per common share. The dividend is payable on November 25, 2026, to stockholders of record on November 11, 2026.

David Nelson, President and Chief Executive Officer of the Company, commented, “Our net income for the first nine months of 2026 has increased 32 percent compared to the first nine months of 2025. Our annualized return on average equity has improved to 16.18 percent for the first nine months of 2026, compared to 14.27 percent for the first nine months of 2025 and our annualized return on average assets has grown to 1.16 percent in the third quarter of 2026. We are producing stronger profitability through margin expansion and expense discipline, while maintaining a strict underwriting culture and strong asset quality. Our balance sheet management strategies have resulted in a reduction in wholesale funding and steady growth in net interest income.”

Mr. Nelson added, “Our balance sheet remains exceptionally strong, supported by solid capital and liquidity levels. Credit quality remains pristine with no loans on nonaccrual status at September 30, 2026. Additionally, this marks our ninth consecutive quarter-end with no loans greater than 30 days past due.”

Third Quarter 2026 Compared to Second Quarter 2026 Overview

  • Quarterly net income was $11.6 million, an increase of $0.5 million, or 5.01 percent, compared to prior quarter.
  • Quarterly return on average equity increased to 16.41 percent, compared to 16.21 percent in prior quarter.
  • Loan balances increased $45.1 million, or 1.5 percent as of September 30, 2026, compared to June 30, 2026.
  • No credit loss expense on loans was recorded in either the third or second quarter of 2026.
  • The allowance for credit losses to total loans was 1.02 percent as of September 30, 2026, compared to 1.03 percent as of June 30, 2026. There were no nonaccrual loans at September 30, 2026 or June 30, 2026. Substandard loans decreased to $13.8 million as of September 30, 2026, from $14.4 million as of June 30, 2026. The substandard loan balances consisted of commercial and commercial real estate loans to two borrowers. In both instances, the Company believes the loans are sufficiently collateralized. Watch list loans decreased from $7.1 million as of June 30, 2026 to $6.7 million as of September 30, 2026. The decreases in substandard and and watch list loans was primarily due to principal payments.
  • Deposits, excluding brokered deposits, decreased $65.8 million, or 2.0 percent, in the third quarter of 2026. Brokered deposits were reduced by $8.5 million. As of September 30, 2026, estimated uninsured deposits, which exclude deposits in a reciprocal deposit network, brokered deposits and public funds protected by state programs, accounted for approximately 28.5 percent of total deposits.
  • Net interest margin, on a fully tax-equivalent basis (a non-GAAP measure), was 2.77 percent for the third quarter of 2026, compared to 2.69 percent for the second quarter of 2026. Net interest income for the third quarter of 2026 was $26.4 million, compared to $25.5 million for the second quarter of 2026. Loan yields increased 8 basis points, to 5.73 percent, in the third quarter of 2026 compared to the second quarter of 2026, while the average balance of loans declined $44.1 million. The cost of interest-bearing deposits increased 3 basis points, to 2.76 percent. The average balance of interest-bearing deposits decreased $36.4 million in the third quarter of 2026 compared to the prior quarter. The comparison of asset yields and cost of interest-bearing deposits is impacted by the 25 basis point increase in the federal funds target rate in September 2026. The average balance of FHLB advances declined $32.1 million in the third quarter of 2026 compared to the prior quarter as matured advances were not renewed.
  • The efficiency ratio (a non-GAAP measure) was 47.81 percent for the third quarter of 2026, compared to 48.78 percent for the second quarter of 2026, primarily due to the increase in tax-equivalent net interest income.
  • The tangible common equity ratio was 6.98 percent as of September 30, 2026, compared to 6.97 percent as of June 30, 2026.

Third Quarter 2026 Compared to Third Quarter 2025 Overview

  • Quarterly net income was $11.6 million, an increase of $2.3 million, or 24.8 percent, compared to prior year.
  • Quarterly return on average equity increased to 16.41 percent, compared to 15.25 percent in prior year.
  • Loan balances were down slightly by $13.7 million at September 30, 2026, or 0.5 percent, compared to September 30, 2025. Changes in the loan portfolio included decreases of $159.0 million in construction, land and land development loans and $52.9 million in commercial loans and an increase of $156.3 million in commercial real estate loans. The change in loan mix included reclassifications resulting from completed construction projects moving to permanent financing and commercial loan restructurings that added real estate as collateral.
  • Deposits, excluding brokered deposits, increased $67.0 million, or 2.2 percent, as of September 30, 2026, compared to September 30, 2025. Brokered deposits were reduced by $102.9 million.
  • Net interest margin, on a fully tax-equivalent basis (a non-GAAP measure), was 2.77 percent for the third quarter of 2026, compared to 2.36 percent for the third quarter of 2025. Net interest income for the third quarter of 2026 was $26.4 million, compared to $22.5 million for the third quarter of 2025. Loan yields increased by 7 basis points in the 3rd quarter of 2026, compared to the third quarter of 2025, while the average balance of loans declined $19.6 million. The cost of interest-bearing deposits decreased by 41 basis points in the third quarter of 2026 compared to the third quarter of 2025. The average balance of interest-bearing deposits declined $41.3 million in the third quarter of 2026 compared to the third quarter of 2025. The comparison of asset yields and cost of interest-bearing deposits is impacted by the 75 basis point decrease in the federal funds target rate in the third and fourth quarters of 2025 and subsequent 25 basis point increase in the federal funds target rate in September 2026.
  • The efficiency ratio (a non-GAAP measure) was 47.81 percent for the third quarter of 2026, compared to 54.06 percent for the third quarter of 2025. The improvement in the efficiency ratio in the third quarter of 2026 compared to the third quarter of 2025 was primarily due to the increase in tax-equivalent net interest income.
  • The tangible common equity ratio was 6.98 percent as of September 30, 2026, compared to 6.40 percent as of September 30, 2025. The increase in the tangible common equity ratio was due to growth in retained earnings.

The Company filed its report on Form 10-Q with the Securities and Exchange Commission today. Please refer to that document for a more in-depth discussion of the Company’s financial results. The Form 10-Q is available on the Investor Relations section of West Bank’s website at www.westbankstrong.com.

The Company will discuss its results in a conference call scheduled for 2:00 p.m. Central Time on Thursday, October 29, 2026. The telephone number for the conference call is 833-461-5787. The meeting ID for the conference call is 761930850. A recording of the call will be available until November 12, 2026, by dialing 833-309-1852. The meeting ID for the replay call is 761930850.

About West Bancorporation, Inc. (Nasdaq: WTBA)

West Bancorporation, Inc. is headquartered in West Des Moines, Iowa. Serving customers since 1893, West Bank, a wholly-owned subsidiary of West Bancorporation, Inc., is a community bank that focuses on lending, deposit services, and trust services for small- to medium-sized businesses and consumers. West Bank has six offices in the Des Moines, Iowa metropolitan area, one office in Coralville, Iowa, and four offices in Minnesota in the cities of Rochester, Owatonna, Mankato and St. Cloud.

Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to the Company’s business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meanings of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may appear throughout this report. These forward-looking statements are generally identified by the words “believes,” “expects,” “intends,” “anticipates,” “projects,” “forecasts,” “plans,” “targets,” “future,” “confident,” “potentially,” “probably,” “outlook,” “may,” “should,” “would,” “could,” “will,” “strategy,” “plan,” “opportunity,” “will be,” “will likely result,” “will continue” or similar references, as well as the negative of such words, or references to estimates, predictions or future events. Forward-looking statements are not historical facts but instead represent management’s current expectations and forecasts regarding future events, many of which are inherently uncertain and outside of our control. Such forward-looking statements are based upon certain underlying assumptions, known and unknown, risks and uncertainties. Because of the possibility that the underlying assumptions are incorrect or do not materialize as expected in the future, actual results may differ, possibly materially, from these forward-looking statements. Risks and uncertainties that may affect future results include, but are not limited to: interest rate risk, including the effects of the recent increase in the benchmark federal funds rate by the Federal Reserve; fluctuations in the values of the securities held in our investment portfolio, including as a result of rising interest rates; competitive pressures, including from non-bank competitors such as credit unions, “fintech” companies and digital asset service providers; technological changes implemented by us and other parties, including third-party vendors, which may be more difficult to implement or more expensive than anticipated or which may have unforeseen consequences to us and our customers, including the development and implementation of tools incorporating artificial intelligence; pricing pressures on loans and deposits; our ability to successfully manage liquidity risk; changes in credit and other risks posed by the Company’s loan portfolio, including declines in commercial or residential real estate values or changes in the allowance for credit losses dictated by new market conditions, accounting standards or regulatory requirements; the concentration of large deposits from certain clients, including those who have balances above current FDIC insurance limits; the threat or imposition of domestic or foreign tariffs or other governmental policies impacting the global supply chain and the value of products produced by our commercial borrowers; effects on the U.S. economy resulting from actions taken by the federal government, including executive orders and immigration enforcement; changes in local, national and international economic conditions, including the level and impact of inflation, and future monetary policies of the Federal Reserve in response thereto, and possible recession; the impact of bank failures or adverse developments at other banks and related negative publicity about the banking industry in general on investor and depositor sentiment regarding the stability and liquidity of banks; changes in legal and regulatory requirements, limitations and costs; changes in customers’ acceptance of the Company’s products and services; the occurrence of fraudulent activity, breaches or failures of our or our third-party partners’ information security controls or cyber-security related incidents, including as a result of sophisticated attacks using artificial intelligence and similar tools; unexpected outcomes of existing or new litigation involving the Company; the monetary, trade and other regulatory policies of the U.S. government; the effects of acts of war or terrorism, including the wars in Iran and Ukraine, ongoing conflicts in the Middle East, and other international military conflicts that can increase levels of political and economic unpredictability, contribute to rising energy and commodity prices, affect global supply chains, increase the volatility of financial markets, and other matters beyond our control; widespread disease, pandemics or epidemics, or other adverse external events; risks related to climate change and the negative impact it may have on our customers and their business; changes to U.S. tax laws, regulations and guidance; potential changes in federal policy and at regulatory agencies; talent and labor shortages; emerging issues related to the development and use of artificial intelligence that could give rise to legal or regulatory action, damage our reputation or otherwise materially harm our business or customers; the availability of future equity and debt issuances and other capital raising opportunities on favorable terms; and any other risks described in the “Risk Factors” sections of reports filed by the Company with the Securities and Exchange Commission (the “SEC”). The Company cautions readers not to place undue reliance on any forward-looking statements. Moreover, any of the forward-looking statements that the Company makes in this report or the documents the Company files with or furnishes to the SEC are based only on information then actually known to the Company and upon management’s beliefs and assumptions at the time they are made, which may turn out to be wrong because of inaccurate assumptions they might make, because of the factors described above or because of other factors that the Company cannot foresee. Forward-looking statements speak only as of the date they are made, and the Company does not undertake and specifically disclaims any obligation to revise or update such forward-looking statements to reflect current or future events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For more information contact:
Jane Funk, Executive Vice President, Treasurer and Chief Financial Officer (515) 222-5766

WEST BANCORPORATION, INC. AND SUBSIDIARY            
Financial Information (unaudited)                            
                             
    As of and for the Quarter Ended   For the Nine Months Ended
KEY PERFORMANCE RATIOS AND OTHER METRICS   September
30, 2026
  June 30,
2026
  March 31,
2026
  December 31,
2025
  September
30, 2025
  September
30, 2026
  September
30, 2025
Return on average assets(1)     1.16 %     1.10 %     1.06 %     0.72 %     0.92 %     1.11 %     0.84 %
Return on average equity(2)     16.41       16.21       15.91       11.33       15.25       16.18       14.27  
Net interest margin(3)(13)     2.77       2.69       2.59       2.47       2.36       2.68       2.30  
Yield on interest-earning assets(4)(13)     5.16       5.10       5.04       5.02       5.13       5.10       5.08  
Cost of interest-bearing liabilities     2.90       2.88       2.90       3.02       3.26       2.89       3.27  
Efficiency ratio(5)(13)     47.81       48.78       49.85       50.21       54.06       48.79       55.60  
Nonperforming assets to total assets(6)     0.00       0.00       0.00       0.00       0.00          
ACL ratio(7)     1.02       1.03       1.02       1.02       1.01          
Loans/total assets     76.96       73.21       74.59       72.47       75.50          
Loans/total deposits     91.58       88.20       89.71       86.54       91.00          
Tangible common equity ratio(8)     6.98       6.97       6.75       6.42       6.40          
                             
COMMON SHARE DATA                            
Earnings per common share (basic)   $ 0.68     $ 0.65     $ 0.62     $ 0.44     $ 0.55     $ 1.96     $ 1.49  
Earnings per common share (diluted)     0.67       0.64       0.61       0.43       0.55       1.93       1.48  
Dividends per common share     0.26       0.25       0.25       0.25       0.25       0.76       0.75  
Book value per common share(9)     15.94       16.49       15.90       15.70       15.06          
Closing stock price     28.51       26.53       23.79       22.19       20.32          
Market price/book value(10)     178.86 %     160.89 %     149.62 %     141.34 %     134.93 %        
Price earnings ratio(11)     10.57       10.18       9.40       12.71       9.31          
Annualized dividend yield(12)     3.65 %     3.77 %     4.20 %     4.51 %     4.92 %        
                             
REGULATORY CAPITAL RATIOS                            
Consolidated:                            
Total risk-based capital ratio     13.43 %     13.46 %     12.99 %     12.77 %     12.54 %        
Tier 1 risk-based capital ratio     10.78       10.77       10.34       10.14       9.93          
Tier 1 leverage capital ratio     9.18       8.91       8.74       8.44       8.51          
Common equity tier 1 ratio     10.21       10.18       9.77       9.56       9.37          
West Bank:                            
Total risk-based capital ratio     13.87 %     13.97 %     13.53 %     13.35 %     13.17 %        
Tier 1 risk-based capital ratio     12.95       13.03       12.61       12.44       12.26          
Tier 1 leverage capital ratio     11.03       10.79       10.66       10.35       10.50          
Common equity tier 1 ratio     12.95       13.03       12.61       12.44       12.26          

(1) Annualized net income divided by average assets.
(2) Annualized net income divided by average stockholders’ equity.
(3) Annualized tax-equivalent net interest income divided by average interest-earning assets.
(4) Annualized tax-equivalent interest income on interest-earning assets divided by average interest-earning assets.
(5) Noninterest expense (excluding other real estate owned expense and write-down of premises) divided by noninterest income (excluding net securities gains/losses and gains/losses on disposition of premises and equipment) plus tax-equivalent net interest income.
(6) Total nonperforming assets divided by total assets.
(7) Allowance for credit losses on loans divided by total loans. 
(8) Common equity less intangible assets (none held) divided by tangible assets.
(9) Includes accumulated other comprehensive loss.
(10) Closing stock price divided by book value per common share.
(11) Closing stock price divided by annualized earnings per common share (basic).
(12) Annualized dividend divided by period end closing stock price.
(13) A non-GAAP measure.
   

 

WEST BANCORPORATION, INC. AND SUBSIDIARY            
Financial Information (unaudited)                    
(in thousands)                    
    As of
CONDENSED BALANCE SHEETS   September
30, 2026
  June
30, 2026
  March
31, 2026
  December
31, 2025
  September
30, 2025
Assets                    
Cash and due from banks   $ 23,155     $ 30,986     $ 40,018     $ 25,171     $ 26,875  
Interest-earning deposits with banks     88,822       260,633       180,218       324,502       109,265  
Securities purchased under agreements to resell     160,444       142,080       141,742       121,413       96,792  
Securities available for sale, at fair value     415,648       446,575       456,410       468,447       537,856  
Federal Home Loan Bank stock, at cost     12,426       15,168       15,180       15,167       15,190  
Loans     2,995,211       2,950,114       2,991,638       3,001,690       3,008,888  
Allowance for credit losses     (30,536 )     (30,530 )     (30,523 )     (30,525 )     (30,515 )
Loans, net     2,964,675       2,919,584       2,961,115       2,971,165       2,978,373  
Premises and equipment, net     105,510       106,626       107,619       108,380       109,212  
Bank-owned life insurance     47,066       46,751       46,500       46,192       45,875  
Other assets     73,930       61,261       62,171       61,807       66,042  
Total assets   $ 3,891,676     $ 4,029,664     $ 4,010,973     $ 4,142,244     $ 3,985,480  
                     
Liabilities and Stockholders’ Equity                    
Deposits   $ 3,270,646     $ 3,344,900     $ 3,334,972     $ 3,468,470     $ 3,306,517  
Borrowings     312,852       374,037       375,221       376,406       389,076  
Other liabilities     36,488       29,685       30,037       31,383       34,754  
Stockholders’ equity     271,690       281,042       270,743       265,985       255,133  
Total liabilities and stockholders’ equity   $ 3,891,676     $ 4,029,664     $ 4,010,973     $ 4,142,244     $ 3,985,480  
                     
    For the Quarter Ended
AVERAGE BALANCES   September
30, 2026
  June
30, 2026
  March
31, 2026
  December
31, 2025
  September
30, 2025
Assets   $ 3,993,933     $ 4,029,324     $ 4,027,218     $ 4,104,279     $ 4,004,769  
Loans     2,940,392       2,984,527       2,971,497       2,982,754       2,959,962  
Deposits     3,335,242       3,347,452       3,348,255       3,418,539       3,333,800  
Stockholders’ equity     281,208       273,967       269,453       259,932       242,245  
                                         

WEST BANCORPORATION, INC. AND SUBSIDIARY            
Financial Information (unaudited)                    
(in thousands)                    
    As of
LOANS   September
30, 2026
  June
30, 2026
  March
31, 2026
  December
31, 2025
  September
30, 2025
Commercial   $ 458,416     $ 463,248     $ 471,423     $ 505,059     $ 511,316  
Real estate:                    
Construction, land and land development     289,616       333,753       376,059       426,833       448,660  
1-4 family residential first mortgages     133,880       130,951       139,118       93,122       87,784  
Home equity     26,331       25,999       27,084       26,088       27,083  
Commercial     2,068,526       1,977,477       1,958,189       1,929,766       1,912,235  
Consumer and other     20,984       21,347       22,257       23,374       24,697  
      2,997,753       2,952,775       2,994,130       3,004,242       3,011,775  
Net unamortized fees and costs     (2,542 )     (2,661 )     (2,492 )     (2,552 )     (2,887 )
Total loans   $ 2,995,211     $ 2,950,114     $ 2,991,638     $ 3,001,690     $ 3,008,888  
Less: allowance for credit losses     (30,536 )     (30,530 )     (30,523 )     (30,525 )     (30,515 )
Net loans   $ 2,964,675     $ 2,919,584     $ 2,961,115     $ 2,971,165     $ 2,978,373  
                     
CREDIT QUALITY                    
Pass   $ 2,977,301     $ 2,931,300     $ 2,952,824     $ 2,952,015     $ 2,973,103  
Watch     6,697       7,112       41,306       52,227       38,672  
Substandard     13,755       14,363       —       —       —  
Doubtful     —       —       —       —       —  
Total loans   $ 2,997,753     $ 2,952,775     $ 2,994,130     $ 3,004,242     $ 3,011,775  
                     
DEPOSITS                    
Noninterest-bearing demand   $ 551,615     $ 553,660     $ 511,013     $ 540,358     $ 512,869  
Interest-bearing demand     436,697       506,574       489,990       577,814       448,731  
Savings and money market – non-brokered     1,677,699       1,705,057       1,731,835       1,739,790       1,677,543  
Money market – brokered     101,979       100,450       86,304       99,718       121,849  
Total nonmaturity deposits     2,767,990       2,865,741       2,819,142       2,957,680       2,760,992  
Time – non-brokered     502,656       469,159       485,658       455,944       462,542  
Time – brokered     —       10,000       30,172       54,846       82,983  
Total time deposits     502,656       479,159       515,830       510,790       545,525  
Total deposits   $ 3,270,646     $ 3,344,900     $ 3,334,972     $ 3,468,470     $ 3,306,517  
                     
BORROWINGS                    
Subordinated notes, net   $ 80,352     $ 80,287     $ 80,221     $ 80,156     $ 80,090  
Federal Home Loan Bank advances     210,000       270,000       270,000       270,000       270,000  
Long-term debt     22,500       23,750       25,000       26,250       38,986  
Total borrowings   $ 312,852     $ 374,037     $ 375,221     $ 376,406     $ 389,076  
                     
STOCKHOLDERS’ EQUITY                    
Preferred stock   $ —     $ —     $ —     $ —     $ —  
Common stock     3,000       3,000       3,000       3,000       3,000  
Additional paid-in capital     38,068       37,312       36,553       37,231       36,473  
Retained earnings     314,605       307,408       300,596       294,259       291,069  
Accumulated other comprehensive loss     (83,983 )     (66,678 )     (69,406 )     (68,505 )     (75,409 )
Total stockholders’ equity   $ 271,690     $ 281,042     $ 270,743     $ 265,985     $ 255,133  
                                         

WEST BANCORPORATION, INC. AND SUBSIDIARY                
Financial Information (unaudited)                    
(in thousands)                    
    For the Quarter Ended
CONSOLIDATED STATEMENTS OF INCOME   September
30, 2026
  June
30, 2026
  March
31, 2026
  December
31, 2025
  September
30, 2025
Interest income:                    
Loans, including fees   $ 42,463   $ 42,031   $ 40,946   $ 41,992     $ 42,198
Securities:                    
Taxable     2,105     2,097     2,143     2,355       2,643
Tax-exempt     634     636     638     677       739
Deposits with banks     2,224     2,130     2,047     2,808       2,087
Securities purchased under agreements to resell     1,769     1,580     1,617     1,370       1,258
Total interest income     49,195     48,474     47,391     49,202       48,925
Interest expense:                    
Deposits     19,376     19,184     19,261     21,112       22,539
Subordinated notes     1,113     1,110     1,104     1,109       1,107
Federal Home Loan Bank advances     1,965     2,274     2,244     2,316       2,292
Long-term debt     371     385     397     459       486
Total interest expense     22,825     22,953     23,006     24,996       26,424
Net interest income     26,370     25,521     24,385     24,206       22,501
Credit loss expense     —     —     —     —       —
Net interest income after credit loss expense     26,370     25,521     24,385     24,206       22,501
Noninterest income:                    
Service charges on deposit accounts     482     476     508     493       491
Debit card interchange income     504     514     472     493       477
Trust services     1,190     1,048     1,010     964       894
Increase in cash value of bank-owned life insurance     316     313     308     317       308
Realized securities losses, net     —     —     —     (3,959 )     —
Other income     253     245     256     800       333
Total noninterest income (loss)     2,745     2,596     2,554     (892 )     2,503
Noninterest expense:                    
Salaries and employee benefits     7,956     7,987     7,632     7,579       7,457
Occupancy and equipment     2,025     2,006     2,006     2,083       2,090
Technology and software     790     822     774     789       794
Data processing     578     545     596     673       663
FDIC insurance     455     444     473     475       637
Professional fees     260     298     278     297       303
Other expenses     1,897     1,665     1,706     1,833       1,606
Total noninterest expense     13,961     13,767     13,465     13,729       13,550
Income before income taxes     15,154     14,350     13,474     9,585       11,454
Income taxes     3,526     3,277     2,902     2,160       2,140
Net income   $ 11,628   $ 11,073   $ 10,572   $ 7,425     $ 9,314
                     
Basic earnings per common share   $ 0.68   $ 0.65   $ 0.62   $ 0.44     $ 0.55
Diluted earnings per common share   $ 0.67   $ 0.64   $ 0.61   $ 0.43     $ 0.55
                                 

WEST BANCORPORATION, INC. AND SUBSIDIARY    
Financial Information (unaudited)        
(in thousands)        
    For the Nine Months Ended
CONSOLIDATED STATEMENTS OF INCOME   September 30, 2026   September 30, 2025
Interest income:        
Loans, including fees   $ 125,440   $ 124,852
Securities:        
Taxable     6,345     8,116
Tax-exempt     1,908     2,224
Deposits with banks     6,401     6,551
Securities purchased under agreements to resell     4,966     1,280
Total interest income     145,060     143,023
Interest expense:        
Deposits     57,821     66,638
Subordinated notes     3,327     3,316
Federal Home Loan Bank advances     6,483     6,786
Long-term debt     1,153     1,508
Total interest expense     68,784     78,248
Net interest income     76,276     64,775
Credit loss expense     —     —
Net interest income after credit loss expense     76,276     64,775
Noninterest income:        
Service charges on deposit accounts     1,466     1,448
Debit card interchange income     1,490     1,401
Trust services     3,248     2,472
Increase in cash value of bank-owned life insurance     937     885
Other income     754     950
Total noninterest income     7,895     7,156
Noninterest expense:        
Salaries and employee benefits     23,575     21,804
Occupancy and equipment     6,037     6,087
Technology and software     2,386     2,371
Data processing     1,719     1,923
FDIC insurance     1,372     1,894
Professional fees     836     914
Other expenses     5,268     5,105
Total noninterest expense     41,193     40,098
Income before income taxes     42,978     31,833
Income taxes     9,705     6,698
Net income   $ 33,273   $ 25,135
         
Basic earnings per common share   $ 1.96   $ 1.49
Diluted earnings per common share   $ 1.93   $ 1.48
         

NON-GAAP FINANCIAL MEASURES

This report contains references to financial measures that are not defined in GAAP. Such non-GAAP financial measures include the Company’s presentation of net interest income and net interest margin on a fully taxable equivalent (FTE) basis and the presentation of the efficiency ratio on an adjusted and FTE basis, excluding certain income and expenses. Management believes these non-GAAP financial measures provide useful information to both management and investors to analyze and evaluate the Company’s financial performance. These measures are considered standard measures of comparison within the banking industry. Additionally, management believes providing measures on a FTE basis enhances the comparability of income arising from taxable and nontaxable sources. Limitations associated with non-GAAP financial measures include the risks that persons might disagree as to the appropriateness of items included in these measures and that different companies might calculate these measures differently. These non-GAAP disclosures should not be considered an alternative to the Company’s GAAP results. The following table reconciles the non-GAAP financial measures of net interest income and net interest margin on a fully taxable equivalent basis and efficiency ratio on an adjusted and FTE basis.

 (in thousands)   For the Quarter Ended   For the Nine Months Ended
    September
30, 2026
  June
30, 2026
  March
31, 2026
  December
31, 2025
  September
30, 2025
  September
30, 2026
  September
30, 2025
Reconciliation of net interest income and net interest margin on a FTE basis to GAAP:                            
Net interest income (GAAP)   $ 26,370     $ 25,521     $ 24,385     $ 24,206     $ 22,501     $ 76,276     $ 64,775  
Tax-equivalent adjustment (1)     76       75       72       70       61       223       186  
Net interest income on a FTE basis (non-GAAP)     26,446       25,596       24,457       24,276       22,562       76,499       64,961  
Average interest-earning assets     3,785,334       3,820,041       3,821,463       3,893,827       3,790,154       3,808,813       3,769,158  
Net interest margin on a FTE basis (non-GAAP)     2.77 %     2.69 %     2.59 %     2.47 %     2.36 %     2.68 %     2.30 %
                             
Reconciliation of efficiency ratio on an adjusted and FTE basis to GAAP:                            
Net interest income on a FTE basis (non-GAAP)   $ 26,446     $ 25,596     $ 24,457     $ 24,276     $ 22,562     $ 76,499     $ 64,961  
Noninterest income     2,745       2,596       2,554       (892 )     2,503       7,895       7,156  
Adjustment for realized securities losses, net     —       —       —       3,959       —       —       —  
Adjustment for losses on disposal of premises and equipment, net     7       28       2       —       —       37       8  
Adjusted income     29,198       28,220       27,013       27,343       25,065       84,431       72,125  
Noninterest expense     13,961       13,767       13,465       13,729       13,550       41,193       40,098  
Efficiency ratio on an adjusted and FTE basis (non-GAAP) (2)     47.81 %     48.78 %     49.85 %     50.21 %     54.06 %     48.79 %     55.60 %

(1) Computed on a tax-equivalent basis using a federal income tax rate of 21 percent, adjusted to reflect the effect of the nondeductible interest expense associated with owning tax-exempt securities and loans. Management believes the presentation of this non-GAAP measure provides supplemental useful information for proper understanding of the financial results, as it enhances the comparability of income arising from taxable and nontaxable sources.
(2) The efficiency ratio expresses noninterest expense as a percent of fully taxable equivalent net interest income and noninterest income, excluding specific noninterest income and expenses. Management believes the presentation of this non-GAAP measure provides supplemental useful information for proper understanding of the Company’s financial performance. It is a standard measure of comparison within the banking industry. A lower ratio is more desirable.

MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1778641&tp_key=e66abcfe8a. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company’s first FDA-approved product is REVTORPYK™ (gedatolisib), a potent pan-PI3K and mTORC1/2 inhibitor that comprehensively blocks the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1, alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with hormone receptor-positive (“HR+”), human epidermal growth factor receptor 2-negative (“HER2-“) locally advanced or metastatic breast cancer (“ABC”). Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study have been released.

Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.

More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis, Minnesota. Further information about Celcuity and its products, including important safety information and full prescribing information can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com  
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

New license agreements drive Q3 results above guidance and increased FY26 outlook
Annualized recurring revenue1 at all-time high of $629 million
Revenue up 17% YoY; Net income up 19% YoY; Adjusted EBITDA2 up 25% YoY

WILMINGTON, Del., Oct. 29, 2026 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a wireless, video, and AI technology research and development company, today announced results for the quarter ended September 30, 2026.

“This was another excellent quarter, with double-digit growth in revenue and profitability and record annualized recurring revenue,” said Liren Chen, President and CEO of InterDigital. “We secured a new PC license through arbitration and advanced our video services program. Building on last quarter’s increase in annual guidance, our strong execution in Q3 supports another increase to the midpoint of our full-year revenue guidance, this time based only on revenue already under contract. We continue to pursue additional business in Q4 to build on these results.”

Recent Business Highlights:

  • Reached agreement with a top PC manufacturer, with final terms to be determined by binding arbitration; we now have licensed 4 of the top 5 PC makers in the world
  • Signed new IoT license agreement with EV charging company KEBA
  • Earned revenue of $193 million up 17% year-over-year
  • Achieved record annualized recurring revenue of $629 million
  • Declared increase in quarterly cash dividend from $0.70 to $0.75 per share
  • Awarded two new injunctions against Disney by Europe’s Unified Patent Court; in total eight injunctions won against Disney out of eight patent cases decided to date
  • Recognized as one of America’s Greatest Companies by Newsweek and one of America’s Growth Leaders by Time

Third Quarter 2026 Financial Summary:

Third quarter 2026 revenue included $36.2 million of catch-up revenue, compared with $17.7 million in third quarter 2025.

  Three Months Ended September 30,
($ in millions, except per share data) 2026   2025   Change
GAAP Results:          
Revenue $193.4   $164.7   17%
Operating expenses $94.1   $88.9   6%
Net income $80.2   $67.5   19%
Net income margin 41%   41%   — ppt
Diluted EPS $2.34   $1.93   21%
Non-GAAP Results:          
Adjusted EBITDA 2 $131.3   $104.9   25%
Adjusted EBITDA margin 2 68%   64%   4 ppt
Non-GAAP Net income 3 $95.7   $78.2   22%
Non-GAAP EPS 3 $3.11   $2.55   22%
Additional Information:          
Revenue by type:          
Annualized recurring revenue $628.9   $588.0   7%
Catch-up revenue $36.2   $17.7   105%
Revenue by program:          
Smartphone $122.6   $136.4   (10)%
CE, IoT/Auto $55.7   $28.2   97%
Streaming and Cloud Services $15.0   $—   N/M
Other $0.1   $0.1   54%

N/M         indicates not meaningful

Return of Capital

(in millions, except per share data) Share Repurchases   Dividends Declared   Reduction of
Debt
  Total Return
of Capital
Shares   Value   Per Share   Value    
Third quarter 2026 <0.1   $18.7   $0.75   $19.3   $83.2   $121.2
                       

Near Term Outlook

The Company has provided an outlook for fourth quarter and full year 2026 in the table below, in both cases based on contracted revenue only and does not include any new agreements or enforcement action results we may sign or receive over the balance of the fourth quarter. Any new agreements and/or enforcement actions we may receive over the balance of the fourth quarter would be additive.

(in millions, except per share data) Q4 2026   Full Year 2026
Revenue $154 – $160   $813 – $819
Adjusted EBITDA 2 $80 – $88   $507 – $515
Diluted EPS $1.04 – $1.27   $8.93 – $9.16
Non-GAAP EPS 3 $1.72 – $1.98   $11.99 – $12.25
       

Convertibility of 2027 Notes

Pursuant to the terms of the Indenture governing InterDigital’s 3.50% Senior Convertible Notes due 2027 (the “Notes”), the Notes are convertible during the calendar quarter ending December 31, 2026. The current conversion rate of the Notes is 13.0351 shares of InterDigital’s Common Stock per $1,000 principal amount of the Notes.

Upon the conversion of any Notes, InterDigital will pay cash up to the aggregate principal amount of the Notes to be converted, and will pay cash, shares of its Common Stock or a combination of cash and shares of its Common Stock for any conversion obligation in excess of the aggregate principal amount being converted, if any, at InterDigital’s election, as set forth in the Indenture governing the Notes.

At the time InterDigital issued the Notes, InterDigital entered into call spread transactions that together were designed to have the economic effect of reducing the net number of shares that will be issued in the event of conversion of the Notes by, in effect, increasing the conversion price of the Notes from InterDigital’s economic standpoint from $76.72 to $105.30. In connection with the Notes issuance, we also issued warrants to acquire, subject to customary anti-dilution adjustments, approximately 6.0 million shares of common stock. Refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Notes, Hedge, and Warrant Transactions” in InterDigital’s Form 10-Q for the quarter ended September 30, 2026 for more information.

As of September 30, 2026, $296.7 million in principal of the 2027 Notes remains outstanding, of which holders have elected to convert $2.2 million principal amount, which will settle in fourth quarter 2026. No incremental outstanding shares will result from such conversions due to the offsetting impact of hedging arrangements.

As of September 30, 2026, warrants to acquire 6.0 million shares of common stock remain outstanding at a strike price of $105.30, subject to adjustment, which mature on a net-share basis beginning September 2027 through April 2028.

Conference Call Information

InterDigital will host a conference call on Thursday, October 29, 2026 at 10:00 a.m. ET to discuss its third quarter 2026 financial performance and other company matters.

For a live webcast of the conference call visit www.interdigital.com and click on the “Webcast” link on the Investors page. The company encourages participants to take advantage of the webcast option.

See below for dial-in details to join the call telephonically:
USA – Toll-Free (800) 715-9871
USA / International Toll +1 (646) 307-1963
Conference ID 9344581  or Conference Name

A replay of the conference call will be available on InterDigital’s website under Events in the Investors section. The replay will be available for one year.

About InterDigital®

InterDigital is a global research and development company focused primarily on wireless, video, artificial intelligence (“AI”), and related technologies. We design and develop foundational technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. We license our innovations worldwide to companies providing such products and services, including makers of wireless communications devices, consumer electronics, IoT devices, cars and other motor vehicles, and providers of cloud-based services such as video streaming. As a leader in wireless technology, our engineers have designed and developed a wide range of innovations that are used in wireless products and networks, from the earliest digital cellular systems to 5G and today’s most advanced Wi-Fi technologies. We are also a leader in video processing and video encoding/decoding technology, with a significant AI research effort that intersects with both wireless and video technologies. Founded in 1972, InterDigital is listed on Nasdaq.

InterDigital is a registered trademark of InterDigital, Inc.

For more information, visit the InterDigital website: www.interdigital.com.

For additional financial measures, refer to our third quarter 2026 Form 10-Q and the financial metrics tracker, which are available on the Investor Relations section of our website.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include information regarding our current beliefs, plans and expectations. Words such as “believe,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “forecast,” “outlook,” “goal,” “could,” “would,” “should,” “if,” “may,” “might,” “future,” “target,” “trend,” “seek to,” “will continue,” “predict,” “likely,” “in the event,” and variations of any such words or similar expressions are intended to identify such forward-looking statements.

Forward-looking statements are made on the basis of management’s current views and assumptions and are not guarantees of future performance. Forward-looking statements, including but not limited to statements regarding our outlook for Q4 and full year 2026, are inherently subject to risks and uncertainties that could cause actual results, and actual events that occur, to differ materially from results contemplated by the forward-looking statements. These risks and uncertainties include, but are not limited to: (i) unanticipated delays or difficulties in the execution of patent license agreements on acceptable terms or at all; (ii) our ability to expand our revenue opportunities by entering into licensing arrangements with streaming and cloud-based service providers; (iii) the initiation of new legal proceedings or the resolution of ongoing legal proceedings, including any awards or judgments relating to such proceedings, and changes in the schedules or costs associated therewith; (iv) our ability to maintain a strong patent portfolio and make strategic decisions related to our intellectual property protection; (v) our ability to successfully integrate Deep Render and to recognize the anticipated benefits of the transaction; (vi) the failure of markets for our technologies to materialize to the extent that we expect; (vii) our continued ability to develop new technologies; (viii) changes in our interpretations of, and assumptions and calculations with respect to the impact on us of, the One Big Beautiful Bill Act, the 2017 Tax Cuts and Jobs Act and other U.S. and non-U.S. tax laws and other tax matters; (ix) the timing and impact of potential regulatory, administrative and legislative matters; (x) the potential effects of macroeconomic conditions or global conflicts; (xi) our ability to hire and retain key personnel; (xii) operational risks, including cybersecurity events, human failures or other difficulties with our information technology systems; and (xiii) risks related to any new accounting standards or our estimates, assumptions and the application of relevant accounting standards, including with respect to revenue recognition.

You should not place undue reliance on the forward-looking statements contained herein, which are made only as of the date of this release. We undertake no duty to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.

Footnotes

1          Annualized recurring revenue (“ARR”) for any quarter is defined as total revenue for the quarter less catch-up revenue for the quarter, multiplied by four. Management believes ARR provides useful information about our financial performance, and our progress toward our 2030 targets. ARR is not a projection or forecast, and actual recurring revenue for any 12-month period will depend on a number of factors beyond our ability to predict or control, including those risks and uncertainties listed above. Additionally, ARR may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

2          Adjusted EBITDA and Adjusted EBITDA margin are supplemental non-GAAP financial measures that InterDigital believes provide investors with important insight into the Company’s ongoing business performance. InterDigital defines Adjusted EBITDA as net income plus income tax provision, other income, net & interest expense, depreciation and amortization, share-based compensation, and other items. Other items include restructuring costs, impairment charges and other non-recurring items. Adjusted EBITDA margin is Adjusted EBITDA over total revenue. These non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The presentation of these financial measures, which are not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. A reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure is provided below.

3          Non-GAAP net income, Non-GAAP earnings per share (“EPS”), and Non-GAAP weighted-average diluted shares are supplemental non-GAAP financial measures that InterDigital believes provide investors with important insight into the Company’s ongoing business performance. InterDigital defines Non-GAAP net income as net income plus share-based compensation, acquisition related amortization, restructuring costs, impairment charges and one-time adjustments, losses on extinguishments of long-term debt, the related income tax effect of the preceding items, and adjustments to income taxes. Non-GAAP EPS is defined as Non-GAAP net income divided by Non-GAAP weighted-average diluted shares, which adjusts the weighted-average number of common shares outstanding for the dilutive effect of the Company’s convertible notes, offset by our hedging arrangements. InterDigital’s computation of these non-GAAP financial measures might not be comparable to similarly named measures reported by other companies. The presentation of these financial measures, which are not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. A reconciliation of each of these metrics to its most directly comparable GAAP financial measure is provided below.

SUMMARY CONSOLIDATED STATEMENTS OF INCOME
(in thousands except per share data)
(unaudited)
 
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
  2026   2025   2026   2025
Revenue $ 193,429     $ 164,682     $ 659,015     $ 675,785  
Operating expenses:              
Research and portfolio development   56,692       53,068       168,934       154,172  
Licensing   24,371       19,715       111,215       61,301  
General and administrative   13,001       16,091       58,001       47,245  
Total operating expenses   94,064       88,874       338,150       262,718  
               
Income from operations   99,365       75,808       320,865       413,067  
               
Interest expense   (8,956 )     (10,019 )     (26,606 )     (29,427 )
Other income, net   9,098       10,188       28,420       35,590  
Income before income taxes   99,507       75,977       322,679       419,230  
Income tax provision   (19,278 )     (8,474 )     (50,749 )     (55,557 )
Net income $ 80,229     $ 67,503     $ 271,930     $ 363,673  
               
Net income per common share:              
Basic $ 3.11     $ 2.62     $ 10.55     $ 14.09  
Diluted $ 2.34     $ 1.93     $ 7.86     $ 10.68  
Weighted-average number of common shares outstanding:              
Basic   25,795       25,797       25,782       25,818  
Diluted   34,214       34,925       34,585       34,051  
               
Cash dividends declared per common share $ 0.75     $ 0.70     $ 2.15     $ 1.90  
                               

SUMMARY CONSOLIDATED CASH FLOWS
(in thousands)
(unaudited)
 
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
  2026   2025   2026   2025
Cash flows from operating activities:              
Net income $ 80,229     $ 67,503     $ 271,930     $ 363,673  
Non-cash adjustments   12,043       90,142       207,520       107,678  
Working capital changes   58,084       238,285       (230,477 )     9,708  
Net cash provided by operating activities   150,356       395,930       248,973       481,059  
Cash flows from investing activities:              
Net sales, maturities, and purchases of short-term investments   13,694       338       25,755       18,325  
Capitalized expenditures and patent costs   (14,141 )     (15,055 )     (45,156 )     (55,262 )
Long-term investments   —       —       1,709       —  
Net cash used in investing activities   (447 )     (14,717 )     (17,692 )     (36,937 )
Cash flows from financing activities:              
Payments on long-term debt and warrants   (83,239 )     (14 )     (171,258 )     (1,298 )
Repurchase of common stock   (18,741 )     (35,252 )     (49,887 )     (66,669 )
Dividends paid   (18,064 )     (15,507 )     (54,150 )     (42,641 )
Other   (7,547 )     (10,646 )     (63,553 )     (36,431 )
Net cash used in financing activities   (127,591 )     (61,419 )     (338,848 )     (147,039 )
Net increase (decrease) in cash, cash equivalents, and restricted cash   22,318       319,794       (107,567 )     297,083  
Cash, cash equivalents, and restricted cash, beginning of period   624,383       528,836       754,268       551,547  
Cash, cash equivalents, and restricted cash, end of period $ 646,701     $ 848,630     $ 646,701     $ 848,630  
                               

SUMMARY CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
 
  September 30, 2026   December 31, 2025
Assets      
Cash, cash equivalents, and short-term investments $ 1,122,603   $ 1,243,160
Accounts receivable   116,170     69,816
Prepaid and other current assets   87,096     74,994
Property & equipment and patents, net   335,401     342,469
Other long-term assets, net   496,396     333,851
Total assets $ 2,157,666   $ 2,064,290
Liabilities and Shareholders’ equity      
Current portion of long-term debt $ 295,750   $ 458,376
Current deferred revenue   294,935     193,722
Other current liabilities   108,785     100,404
Long-term deferred revenue   138,363     135,882
Long-term debt & other long-term liabilities   71,431     74,786
Total liabilities   909,264     963,170
Total shareholders’ equity   1,248,402     1,101,120
Total liabilities and shareholders’ equity $ 2,157,666   $ 2,064,290
           

RECONCILIATION OF NON-GAAP MEASURES

The following tables present InterDigital’s GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the third quarter ended September 30, 2026 and 2025:

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
  (in thousands)   (in thousands)
  2026   2025   2026   2025
Net income $ 80,229     $ 67,503     $ 271,930     $ 363,673  
Income tax provision   19,278       8,474       50,749       55,557  
Other income, net & interest expense   (142 )     (169 )     (1,814 )     (6,163 )
Depreciation and amortization   19,663       19,804       58,353       57,482  
Share-based compensation   13,316       9,301       47,758       30,635  
Other items 4   (1,034 )     —       221       (483 )
Adjusted EBITDA 2 $ 131,310     $ 104,913     $ 427,197     $ 500,701  
                               

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
  (in thousands, except
for per share data)
  (in thousands, except
for per share data)
  2026   2025   2026   2025
Net income $    80,229     $    67,503     $   271,930     $   363,673  
Share-based compensation        13,316              9,301            47,758            30,635  
Acquisition related amortization          7,998              9,058            23,976            26,608  
Other operating items 4         (1,034 )                 —                 221               (483 )
Other non-operating items 5               —                   —               (967 )                 —  
Related income tax effect of above items         (4,259 )           (3,855 )         (14,907 )         (11,920 )
Adjustments to income taxes           (566 )           (3,771 )         (11,533 )           (9,337 )
Non-GAAP net income 3 $    95,684     $    78,236     $   316,478     $   399,176  
               
Weighted-average dilutive shares – GAAP        34,214            34,925            34,585            34,051  
Less: Dilutive impact of the Convertible Notes          3,471              4,276              3,845              3,912  
Weighted-average dilutive shares – Non-GAAP 3        30,743            30,649            30,740            30,139  
               
Diluted EPS $        2.34     $        1.93     $        7.86     $      10.68  
Non-GAAP EPS 3 $        3.11     $        2.55     $      10.30     $      13.24  
                               

4     Other items in the above tables include one-time net expenses related to litigation fee reimbursements.
5     Other non-operating items includes gains from observable price changes of our long-term strategic investments.

The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial measures for the fourth quarter of 2026 and full year fiscal 2026 included in this release:

  Outlook
  (in millions)
  Q4 2026   Full Year 2026
Net income $35 – $43   $307 – $315
Income tax provision 10   61  
Other income, net & interest expense                         —                           (2 )
Depreciation and amortization 20   78  
Share-based compensation 15   63  
Adjusted EBITDA 2 $80 – $88   $507 – $515
       

  Outlook
  (in millions)
  Q4 2026   Full Year 2026
Net income $35 – $43   $307 – $315
Share-based compensation 15     63  
Acquisition related amortization 8     32  
Other non-operating items —     (1 )
Related income tax effect of above items (5 )   (20 )
Adjustments to income taxes —     (12 )
Non-GAAP net income 3 $53 – $61   $369 – $377
       
Weighted-average dilutive shares – GAAP 33.8     34.4  
Less: Dilutive impact of the Convertible Notes 3.0     3.6  
Weighted-average dilutive shares – Non-GAAP 3 30.8     30.8  
       
Diluted EPS $1.04 – $1.27   $8.93 – $9.16
Non-GAAP EPS 3 $1.72 – $1.98   $11.99 – $12.25
       

CONTACT: InterDigital, Inc.
  Email: investor.relations@interdigital.com
   +1 (302) 300-1857

SEATTLE, Oct. 29, 2026 (GLOBE NEWSWIRE) — Marchex, Inc. (NASDAQ: MCHX) (“Marchex” or the “Company”), a vertically focused, AI-driven conversation analytics, customer acquisition and optimization company, today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, November 10, 2026, after the close of the market. At that time, Marchex will post the press release in the Press Center section of its corporate website (https://www.marchex.com/about-us/press/). 

Following the release, management will hold a conference call at 5:00 p.m. ET on Tuesday, November 10, 2026, to discuss the results and outlook for the company. A live webcast will be available on the Investors section of the Marchex website (http://investors.marchex.com/financial-information/quarterly-results), where an archived version of the webcast will also be available two hours after completion of the call.

About Marchex

Marchex and Archenia together harness proprietary AI-powered conversational intelligence and advanced customer acquisition technologies to transform consumer intent into actionable, outcome-driven business results. The combination of Marchex’s prescriptive analytics and omnichannel intelligence with Archenia’s AI-verified qualification, natural-language analytics, and automated decisioning capabilities creates a highly differentiated customer acquisition and optimization technology platform. 

Leveraging real-time AI signals, machine-learning models, and deep vertical market expertise, the Company identifies consumer intent, improves qualification accuracy, and delivers verified outcomes such as high-intent conversations, appointments, and sales. Serving market-leading companies across major verticals including automotive, insurance, home services, healthcare, and advertising/media, Marchex empowers organizations to optimize customer engagement and drive revenue growth through AI-driven insights, actions, and outcomes.

Please visit www.marchex.com, www.marchex.com/press-awards-recognition/, or follow Marchex on LinkedIn, where Marchex discloses material information from time to time about the Company, its financial information, and its business.

For further information, contact:
Marchex Investor Relations
Email: ir@marchex.com

Company intends to explore future opportunities in interceptor drone and counter-drone systems, cybersecurity and critical infrastructure protection

BOCA RATON, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) — Powell Max Limited (Nasdaq: PMAX) (“Powell Max,” “PMAX” or the “Company”) today announced its intention to enter the defense and security sector. The Company plans to do so through a strategy of acquiring and consolidating complementary defense, technology, manufacturing and protection businesses.

The first part of this strategy is the Company’s continued pursuit of the previously announced proposed acquisition of the remaining ownership interests in Blackrod Holdings, LLC (“Blackrod”). Blackrod holds the exclusive rights to manufacture and sell Remington Firearms. As of the date of this release, the proposed Blackrod transaction is the only acquisition that is the subject of a letter of intent or agreement with the Company. The Company has not entered into a letter of intent or definitive agreement with any other company, including any company involved in the military technology, cybersecurity, drones, counter-drone technology or any other defense or security sector.

PMAX may also evaluate opportunities in related areas of interest that include interceptor drone systems, counter-drone technologies, cybersecurity, military support, protective equipment and critical infrastructure security. These areas reflect the Company’s exploratory strategy only. They do not represent pending, imminent or committed transactions. The Company’s long-term goal is to build a diversified operating group serving the physical and digital security needs of eligible government, military, law enforcement and commercial customers in the United States and approved international markets.

As part of this strategy, PMAX may seek to acquire controlling interests in businesses that offer established products, specialized technology, manufacturing capacity or service capabilities. Where appropriate, the Company may also consider minority investments, joint ventures, licensing arrangements and strategic partnerships. The Company’s objective over time is to develop an integrated defense business, with disciplined capital allocation and accountability at each operating company.

“We intend to build a defense and security business that brings together the products, technology and manufacturing capabilities needed to protect people, critical assets and national interests,” said Geordan Pursglove, Chairman and Chief Executive Officer of Powell Max. “The proposed Remington transaction is the first step toward that goal. We plan to explore opportunities where we believe a well-capitalized group could help businesses develop and grow. We intend to pursue acquisitions only at sensible valuations and to focus on capabilities that customers can use.”

Building a Defense Business Through Acquisitions and Integration

PMAX intends to pursue a roll-up strategy to assemble businesses with complementary capabilities and identifiable opportunities to work together. Under the proposed model, the parent company would oversee capital allocation, financial reporting and risk management. Each operating team would remain responsible for its customer relationships, product performance and business execution.

If the Company completes acquisitions, potential benefits could include coordinated purchasing, access to additional manufacturing resources, joint product development, broader distribution and shared administrative services. The Company would pursue integration only where it is expected to improve performance, and would seek to preserve specialized engineering talent, customer relationships and each business’s distinct requirements. Any expected savings or commercial benefits would be evaluated for each transaction rather than assumed across the portfolio, and there can be no assurance that any such benefits would be realized.

In evaluating potential opportunities, the Company intends to prioritize businesses with a clear customer need, defensible capabilities and a credible path to sustainable cash generation. Its evaluation would consider product readiness, intellectual property rights, customer concentration, contract terms, working capital requirements, production capacity and the cost of supporting a business after acquisition.

Remington Firearms as a Potential Manufacturing Foundation

PMAX intends to continue pursuing the proposed acquisition of the remaining ownership interests in Blackrod. In September 2026, PMAX previously announced an initial stand-alone 1.5% equity investment in Blackrod.

The Company’s September 2026 agreement with Blackrod provides the Company with an exclusive negotiating period of up to 12 months to acquire the remaining equity of Blackrod. Any such acquisition would require a definitive agreement, satisfaction of applicable conditions, and any necessary financing and approvals. This announcement does not represent completion of that acquisition, and there can be no assurance that a definitive agreement will be signed or that the transaction will be completed.

If completed, the acquisition could provide the planned group with an established firearms business, a recognized American brand and manufacturing capabilities at Remington’s LaGrange, Georgia facility. PMAX would seek to support Remington’s existing commercial business while evaluating potential opportunities in law enforcement, government procurement and other authorized markets. Entry into any additional market would depend on suitable products, customer qualification and applicable legal and regulatory requirements.

Advanced Interceptor Drones and Counter-Drone Systems

The Company has identified interceptor drone and counter-drone systems as a priority area of interest for its planned defense strategy. PMAX has not entered into a letter of intent or definitive agreement with any company in this sector. In the future, PMAX may evaluate businesses and technologies focused on protection against unauthorized or hostile unmanned aircraft, including interceptor platforms, threat detection and tracking, supporting sensors, command software and related services.

Areas of potential interest include solutions that protect military personnel and installations, airports, ports, energy facilities, industrial sites and other critical assets. Any evaluation would emphasize demonstrated performance, reliability, affordability, manufacturing scalability and compatibility with customers’ existing systems.

PMAX may also consider adjacent unmanned systems used for authorized surveillance, inspection, logistics and situational awareness. Potential opportunities could involve established manufacturers, specialized technology providers or development partnerships. The Company would disclose any material transaction if and when it is entered into, as required.

Cybersecurity and Secure Communications

PMAX may, in the future, evaluate cybersecurity businesses that help government and commercial customers protect networks, sensitive information, connected equipment and industrial operations. The Company has not entered into a letter of intent or definitive agreement with any cybersecurity company. Areas of interest include AI-enabled threat detection, managed security services, threat monitoring, incident response, identity and access management, cloud security and protection of operational technology.
The Company may also consider secure communications, data protection and software that supports coordination across physical security and cyber defense systems. In any evaluation, the Company would look for durable customer relationships, qualified technical personnel and opportunities for recurring service revenue. It would also assess the liabilities and performance obligations that come with protecting customer systems.

Protection and Critical Infrastructure Security

PMAX may also explore potential future acquisitions involving protective equipment, facility security, access control, perimeter monitoring and integrated security services. Potential end markets include military installations, government facilities, utilities, transportation networks, data centers, communications infrastructure and industrial operations.

Areas of interest could include body armor and other personal protective equipment, specialized protective materials, emergency preparedness products, physical security systems and resilience services. The Company would evaluate whether these capabilities could be combined with surveillance, counter-drone and cybersecurity offerings to address customer needs across multiple layers of protection.

Military Support and Defense Industrial Capabilities

Additional areas of interest may also include precision manufacturing, defense electronics, ruggedized components, power systems, specialized vehicles, maritime security equipment and other products used by defense and security customers. PMAX may also consider maintenance, repair, training, logistics and lifecycle support businesses that help customers keep equipment and facilities operational.

These areas of interest may extend to suppliers to larger defense contractors, as well as businesses that sell directly to eligible end users. Any acquisition decision would focus on the strength of the target’s products and services, its ability to fulfill customer obligations, and the investment required to sustain quality and delivery.

Capital Discipline and Transaction Execution

PMAX intends to evaluate each potential transaction against financial, operational and strategic criteria. These include purchase price, debt and contingent liabilities, funding requirements, integration costs, management capability and the expected contribution to the group over time. Potential financing structures could include cash, equity, debt, seller financing or a combination, depending on the transaction and available capital.

The Company’s ability to execute this strategy will depend in part on obtaining financing on acceptable terms, which may not be available. Equity financing could dilute existing shareholders, and debt financing could increase financial obligations and impose operating restrictions. As of the date of this release, the Company has not secured funding for the proposed roll-up strategy or for any particular acquisition, including the proposed Blackrod transaction.

PMAX plans to develop leadership and oversight appropriate for a defense operating group, including expertise in manufacturing, engineering, government contracting and cybersecurity. The structure of any prospective acquisition would be evaluated in light of ownership, governance, security and customer eligibility requirements. Any transaction involving affiliated parties would be subject to appropriate conflict review and applicable approvals.

Global Reach and Market Access

The Company’s long-term goal is to build a business with the potential to serve U.S. customers and authorized customers in allied and other approved international markets. Any international reach would depend on the capabilities acquired, customer demand and the authorizations required for each product, service and jurisdiction.

Before committing to any transaction or market entry, PMAX would assess applicable requirements. These include export controls, sanctions, firearms licensing, procurement rules, foreign ownership restrictions, and any security clearances or other authorizations relevant to a target business.

Planned Next Steps

PMAX’s intended priorities are to advance the proposed Blackrod transaction, identify potential defense and security acquisition candidates, assess financing alternatives and develop an operating structure capable of supporting multiple businesses. The sequencing of any future transactions would depend on readiness, financing availability, valuation and strategic fit.

The Company expects to provide updates as material developments occur and as disclosure is appropriate. The planned strategy does not establish an acquisition timetable, a minimum number of transactions, a revenue target or any assurance of financial results. There can be no assurance that the Company will be successful in identifying suitable acquisition opportunities or, if such opportunities are identified, that the Company will be able to negotiate or enter into definitive agreements, consummate any proposed transactions, or secure terms acceptable to the Company. Any potential transaction would remain subject to applicable due diligence, financing requirements, necessary approvals and other customary conditions. Any future change to the Company’s name, branding or trading symbol would be considered separately and announced if approved.

About Powell Max Limited

Powell Max Limited (Nasdaq: PMAX) currently provides financial communications services supporting Hong Kong capital markets, including reporting, printing, translation and related services for companies and their advisers. The Company is headquartered in Hong Kong and maintains a Delaware subsidiary with corporate personnel in Boca Raton, Florida. PMAX is pursuing expansion opportunities, including its announced investment in Blackrod Holdings, LLC and the proposed defense and security strategy described in this release.

Forward-Looking Statements

This release contains forward-looking statements, including statements concerning PMAX’s proposed expansion into defense and security; its acquisition and consolidation strategy; the proposed Blackrod transaction; potential future investments in drones, cybersecurity, protection, manufacturing and support services; financing plans; integration; market access; and anticipated operating benefits. These statements reflect the Company’s current intentions and expectations and are subject to change.

Actual results may differ materially because of risks and uncertainties, including: the failure to enter into a definitive agreement for, or to complete, the proposed Blackrod transaction, including the expiration or earlier termination of the exclusive negotiating period; the inability to identify suitable targets, agree on definitive terms, obtain financing or approvals, or complete transactions; shareholder dilution and borrowing costs; undisclosed liabilities; integration difficulties; loss of key personnel or customers; product development, testing and manufacturing challenges; intellectual property disputes; product liability and cybersecurity incidents; export restrictions, licensing and foreign ownership requirements; government procurement eligibility and spending changes; supply constraints; competition; geopolitical developments; and the Company’s limited operating history in the defense and security sector. Expected efficiencies, revenue opportunities and other benefits may not be achieved. The proposed strategy and transactions are not assurances of future performance.

Readers should consider these statements together with the risk disclosures in the Company’s most recent Annual Report on Form 20-F and subsequent filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. Except as required by law, the Company assumes no obligation to update or revise any forward-looking statement to reflect later events or information.

Investors Contact:  

IR@PMAXltd.com

  • Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.
  • Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels substantially exceeding those achieved by drug-eluting stents and drug-coated balloons.
  • The Virtue Trial, a pivotal, head-to-head, randomized controlled IDE trial of Virtue SAB versus a commercially available drug-coated balloon in coronary in-stent restenosis, is currently enrolling.

NEW HOPE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) —  Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, today announced that its Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) will be featured in a presentation at Transcatheter Cardiovascular Therapeutics (“TCT”) 2026. TCT, the Cardiovascular Research Foundation’s annual scientific symposium and the world’s premier educational meeting in interventional cardiovascular medicine, will take place October 31–November 3, 2026, at the San Diego Convention Center in San Diego, California.

The presentation will be delivered by Allen Jeremias, MD, Co-Principal Investigator of the Virtue Trial and Director of Interventional Cardiology Research and Director of the Cardiac Catheterization Laboratory at St. Francis Hospital & Heart Center. Dr. Jeremias will review the differentiated mechanism of action of Virtue SAB, the preclinical and clinical evidence supporting it, and the design of the Virtue Trial, the Company’s actively enrolling U.S. Investigational Device Exemption (“IDE”) pivotal trial comparing Virtue SAB head-to-head with the AGENT™ paclitaxel-coated balloon for the treatment of coronary in-stent restenosis (“ISR”) (NCT07045194).

Presentation Details

The Virtue Sirolimus AngioInfusion Balloon (SAB): Differential Mechanism, Clinical Benefit, and Pivotal IDE Trial Design (Sunday, November 1, 2026, 9:03–9:10 a.m. PT)

  • Session: TCT Innovation 2: Innovations in Intravascular Imaging and Coronary Technologies
  • Location: Innovation Theater, Sails Pavilion, Upper Level, San Diego Convention Center
  • Presenter: Allen Jeremias, MD

The presentation will focus on three key points related to Virtue SAB:

  • A fundamentally different approach to sirolimus delivery, uptake, and extended release: Sirolimus is the proven antiproliferative drug with well-established safety and effectiveness, but its optimal benefit depends on achieving and sustaining sufficient drug concentrations in tissue through the healing period. Coating-based drug delivery is limited by dose, drug loss in transit, and uneven transfer and diffusion from the surface. Virtue SAB is designed to infuse a large liquid volume of submicron, particle-encapsulated SirolimusEFR directly into the vessel wall through a non-coated, microporous AngioInfusion Balloon to inhibit proliferation and modulate inflammation, the key drivers of restenosis.
  • Promising preclinical and clinical evidence: Published preclinical data showed that Virtue SAB achieved sirolimus tissue concentrations exceeding those of published drug-eluting stents and drug-coated balloons benchmarks through the critical healing period. In the SABRE study in coronary ISR, Virtue SAB achieved a low three-year target lesion failure rate of 14.3% in all treated patients (intent-to-treat analysis), with no additional target lesion revascularizations between years one and three.
  • The head-to-head, randomized design of the Virtue Trial: The Virtue Trial is a prospective, multicenter, randomized, single-blind, non-inferiority trial with a planned enrollment of approximately 740 patients comparing Virtue SAB with the commercially available AGENT™ paclitaxel-coated balloon.

Dr. Jeremias commented, “Patients with coronary in-stent restenosis frequently face renewed narrowing of a previously treated artery that requires another intervention. We need more durable treatment options that better address this recurring problem without adding another permanent layer of metal inside the artery. Virtue SAB offers the potential to achieve better vessel healing following intervention through optimized sirolimus drug delivery via balloon-based infusion. The Virtue Trial is an opportunity to determine whether this novel approach can translate into meaningful clinical benefit for patients. I look forward to sharing this innovative technology and the pivotal IDE trial design with the TCT community.”

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities.

AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial, and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has two FDA Breakthrough Device Designations. The BACKBEAT Global Pivotal Trial evaluating AVIM Therapy in this population has completed enrollment.

Virtue SAB is a first-of-its-kind, non-coated drug delivery AngioInfusion balloon system designed to infuse a large liquid dose of a proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB exceeded the published tissue concentrations of leading limus drug-eluting stents and demonstrated positive three-year clinical data in coronary ISR in the SABRE study, a multicenter, prospective, independent core laboratory–adjudicated pilot clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease, and below-the-knee peripheral artery disease, in each case, within specified parameters. The Virtue Trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis is currently enrolling patients.

CAUTION: Investigational device. Limited by United States law to investigational use.

For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the enrollment, timing, implementation and design of the Virtue Trial and the Company’s other ongoing pivotal trials, the ability of data from the Virtue Trial to support regulatory approval in the U.S., realizing the clinical and commercial value of AVIM Therapy and Virtue SAB, the potential safety and efficacy of the Company’s product candidates, and the ability of the Company’s partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 12, 2026, and in its subsequent Quarterly Reports on Form 10-Q.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Contacts

Investor Contact:
Silas Newcomb
Orchestra BioMed
snewcomb@orchestrabiomed.com

Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com

Strategic relocation strengthens the Company’s presence in a major international business hub and supports its expanding global operations and partnerships

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) — Axe Compute Inc. (NASDAQ: AGPU), a neocloud AI infrastructure platform delivering dedicated enterprise GPU compute capacity at global scale, today announced the relocation of its corporate headquarters from Pittsburgh, Pennsylvania, to Miami, Florida. The Company’s new headquarters will be located at 801 Brickell Avenue, Suite 510, Miami, FL 33131.

The relocation establishes Axe Compute’s corporate headquarters in one of the United States’ leading international business and financial centers, providing greater proximity to strategic partners, investors and a growing network of global business relationships. With its international connectivity, access to capital and expanding technology ecosystem, Miami offers a strategic base from which Axe Compute can support its worldwide operations and pursue new opportunities across the global AI infrastructure market.

The move also reflects Axe Compute’s broader commitment to strengthening its corporate presence as it scales its AI infrastructure platform, deepens enterprise relationships and expands its international reach.

“Miami has become one of the fastest-growing centers for finance and technology in the United States, and a gateway for international business, which makes it a natural home for a global company serving a global client base,” said Christopher Miglino, Chief Executive Officer of Axe Compute. “Being here brings us closer to our partners, gives them better international access to us, and puts us at the intersection of the capital and talent building the next generation of AI infrastructure. Miami’s favorable tax treatment for corporations and individuals also helps us attract and retain top talent. We look forward to expanding our footprint in Miami.”

About Axe Compute Inc.

Axe Compute Inc. (NASDAQ: AGPU) is a neocloud AI infrastructure platform built on a fundamental premise: AI innovation should not be constrained by hardware choice or availability. The company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models. Axe Compute provides the design, deployment, ownership, and operation of large-scale, dedicated AI infrastructure worldwide, supported by enterprise-grade SLAs and operational expertise. For more information, visit axecompute.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company’s headquarters relocation, operations and growth plans. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.

Investor Relations Contact:

Erin McMahon
Chief Marketing Officer & Head of Investor Relations
IR@axecompute.com

Multi-line Hybrid System deployment, sourced at INTERPHEX, extends TOMI’s integrated automated SteraMist iHP decontamination platform into Latin American pharmaceutical manufacturing

FREDERICK, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced it has received a three-phase order valued at approximately $402,000 from Zeyco, a Mexican company dedicated to developing and manufacturing medicines and medical devices, as a global player in the market of dental anesthetics injectable cartridges.

The order covers the phased deployment of SteraMist ionized Hydrogen Peroxide (iHP) decontamination across three aseptic manufacturing lines at Zeyco’s facility in Guadalajara, Jalisco, including the rooms supporting the filling of injectable solutions. It also includes installation, validation and qualification services, hydrogen peroxide monitoring equipment, and an initial supply of BIT Solution.

The deployment is built on SteraMist’s Hybrid configuration, which connects a SteraMist Environment System generator to ceiling-mounted applicators through a central docking station. This allows multiple connected rooms to be decontaminated from one control point without moving equipment between spaces.

  • Phase 1: A SteraMist Environment System with three mobile applicators, plus a three-applicator Hybrid installation on Manufacturing Line No. 2.
  • Phase 2: A three-applicator Hybrid installation on Manufacturing Line No. 1, powered by the same Environment System generator.
  • Phase 3: A second Environment System generator and a six-applicator Hybrid network for Manufacturing Line No. 3.

Once complete, Zeyco will operate two generators supporting 12 ceiling-mounted Hybrid applicators across three lines. The two generators can treat Line No. 3 in full, or Lines No. 1 and 2 simultaneously. Each phase includes on-site installation, qualification (IQ/OQ/PQ), and operator training.

“For more than 45 years, Zeyco has built its reputation on the quality of the medicines and medical devices we deliver to patients in Mexico and abroad,” said Alejandro Zepeda Sahagun, Pharmaceutical Plant Director of Zeyco. “As we strengthen our aseptic manufacturing operations, we needed a decontamination platform that is validated, repeatable and practical to run across every line. SteraMist iHP technology gives us a system we can grow into phase by phase, with the documentation and on-site support our quality team requires.”

“Zeyco’s decision to standardize three aseptic manufacturing lines with SteraMist reflects what we are seeing across the pharmaceutical market: manufacturers want validated, repeatable decontamination that fits inside their production schedule,” said Elissa J. (E.J.) Shane, Chief Operating Officer of TOMI Environmental Solutions. “A phased, multi-line commitment of this kind builds our installed base in Latin America and supports recurring BIT Solution demand for years to come.”

To learn more, contact TOMI at info@tomimist.com or visit SteraMist.com.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company providing environmental disinfection and bio-decontamination solutions through manufacturing, sales, and licensing of its Binary Ionization Technology® (BIT®) platform. Developed under a defense grant with DARPA, BIT® utilizes low-percentage hydrogen peroxide to produce ionized hydrogen peroxide (iHP®) fog. SteraMist® products serve hospitals, laboratories, government and military installations, cruise ships, office buildings, schools, restaurants, food processing facilities, and residences, delivering protection against a broad range of bacteria, viruses, mold, mycotoxins, and biological and chemical warfare agents. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the life sciences sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT: 
John Nesbett/Zach Nevas
IMS Investor Relations 
tomi@imsinvestorrelations.com  

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.